Anixa Biosciences Company Insiders

ANIX Stock  USD 3.23  0.10  3.19%   
Slightly above 66 percent of all Anixa Biosciences' insiders are acquiring. The analysis of the overall insider sentiment regarding Anixa Biosciences suggests that a large number of insiders are confidant. Anixa Biosciences employs about 4 people. The company is managed by 14 executives with a total tenure of roughly 80 years, averaging almost 5.0 years of service per executive, having 0.29 employees per reported executive.
Amit Kumar  Chairman
Chairman of the Board and Presidentident, CEO

Anixa Biosciences' Insider Buying Vs Selling

66

 
Selling
 
Buying

Latest Trades

2024-03-15Arnold M BaskiesAcquired 10000 @ 3.63View
2023-07-31Amit KumarDisposed 11800 @ 3.57View
2023-07-20Michael CatelaniAcquired 5500 @ 3.64View
Monitoring Anixa Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Anixa Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Anixa Biosciences' future performance. Based on our forecasts, it is anticipated that Anixa will maintain a workforce of slightly above 30 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Anixa Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.2809) % which means that it has lost $0.2809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4302) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.57 in 2024. Return On Assets is likely to drop to -0.46 in 2024. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 30.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 181.4 K in 2024.
Common Stock Shares Outstanding is likely to rise to about 37.4 M in 2024, whereas Net Loss is likely to drop (12.8 M) in 2024.

Anixa Biosciences Workforce Comparison

Anixa Biosciences is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 17,815. Anixa Biosciences adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Anixa Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Anixa Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2023-12-01
2.0
2
1
 17,117 
 16,000 
2023-09-01
0.6
3
5
 165,500 
 287,217 
2022-09-01
0.5
2
4
 680,000 
 1,471,900 
2022-06-01
8.0
8
1
 265,095 
 16,000 
2021-06-01
11.0
11
1
 2,916,634 
 1,500,000 
2021-03-01
5.0
5
1
 85,600 
 200,000 
2019-12-01
8.0
8
1
 845,912 
 0.00 
2019-09-01
3.8
19
5
 1,419,000 
 440,000 
2018-09-01
2.3333
7
3
 321,842 
 20,000 
2018-06-01
4.0
4
1
 4,100,000 
 25,000 
2017-12-01
1.0
1
1
 2,400 
 2,400 
2017-09-01
1.7222
31
18
 2,118,400 
 606,000 
2017-06-01
7.0
7
1
 35,995 
 5,995 
2016-12-01
0.4
2
5
 52,000 
 30,804 
2016-06-01
3.75
15
4
 14,004 
 4,000 
2015-12-01
0.1667
1
6
 4,000 
 20,000 
2015-03-01
1.4815
40
27
 28,591,583 
 27,230,000 
2014-12-01
1.0
1
1
 70,000 
 70,000 
2014-09-01
3.5
7
2
 3,500,000 
 2,000 
2014-06-01
2.0
2
1
 305,000 
 5,000 
2013-12-01
5.0
5
1
 6,050,000 
 16,000 
2013-09-01
0.4
6
15
 2,397,235 
 2,592,450 
2012-12-01
2.0
4
2
 1,180,000 
 8,000,000 
2012-09-01
6.5
26
4
 2,886,000 
 12,000,000 
2011-06-01
2.0
4
2
 1,260,000 
 560,000 
2011-03-01
8.0
8
1
 6,720,000 
 700,000 
2009-12-01
2.5
5
2
 1,360,000 
 200,000 
2007-12-01
4.0
4
1
 1,435,000 
 0.00 
2007-09-01
1.0
3
3
 1,220,000 
 1,220,000 
2006-12-01
0.375
6
16
 1,900,000 
 2,365,905 
2006-09-01
1.0
1
1
 20,000 
 20,000 
2006-03-01
1.0
1
1
 10,550 
 15,000 
2005-12-01
4.0
4
1
 1,200,000 
 15,000 
2005-09-01
1.0
1
1
 16,025 
 10,000 
2004-06-01
5.5
11
2
 860,000 
 40,000 

Anixa Biosciences Notable Stakeholders

An Anixa Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Anixa Biosciences often face trade-offs trying to please all of them. Anixa Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Anixa Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Amit KumarChairman of the Board and Presidentident, CEOProfile
Michael CatelaniCFO, COOProfile
Arnold BaskiesDirectorProfile
Richard WilliamsIndependent DirectorProfile
John MonahanIndependent DirectorProfile
John MonanhanIndependent DirectorProfile
David CavalierDirectorProfile
Dale FoxIndependent DirectorProfile
Lewis TittertonIndependent DirectorProfile
Bruce JohnsonIndependent DirectorProfile
Dean KrouchIR Contact OfficerProfile
John RoopSenior EngineeringProfile
Pamela GarzoneChief OfficerProfile
Thomas SchlumpbergerEx DiagnosticsProfile

About Anixa Biosciences Management Performance

The success or failure of an entity such as Anixa Biosciences often depends on how effective the management is. Anixa Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Anixa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Anixa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed(0.54)(0.57)
Return On Assets(0.44)(0.46)
Return On Equity(0.46)(0.49)
The data published in Anixa Biosciences' official financial statements usually reflect Anixa Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Anixa Biosciences. For example, before you start analyzing numbers published by Anixa accountants, it's critical to develop an understanding of what Anixa Biosciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Anixa Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anixa Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Anixa Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anixa Biosciences. Please utilize our Beneish M Score to check the likelihood of Anixa Biosciences' management manipulating its earnings.

Anixa Biosciences Workforce Analysis

Traditionally, organizations such as Anixa Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Anixa Biosciences within its industry.

Anixa Biosciences Manpower Efficiency

Return on Anixa Biosciences Manpower

Revenue Per Employee52.5K
Revenue Per Executive15K
Net Loss Per Employee2.5M
Net Loss Per Executive709.3K
Working Capital Per Employee5.8M
Working Capital Per Executive1.7M
When determining whether Anixa Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anixa Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anixa Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anixa Biosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Anixa Stock analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is Anixa Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anixa Biosciences. If investors know Anixa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anixa Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Revenue Per Share
0.007
Return On Assets
(0.28)
Return On Equity
(0.43)
The market value of Anixa Biosciences is measured differently than its book value, which is the value of Anixa that is recorded on the company's balance sheet. Investors also form their own opinion of Anixa Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Anixa Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anixa Biosciences' market value can be influenced by many factors that don't directly affect Anixa Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anixa Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anixa Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anixa Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.